Mentor’s Stock Jumps In Q3 On Silicone Implant “Approvable” Letter
This article was originally published in The Gray Sheet
Executive Summary
FDA's "approvable" letter to Mentor for the Memory Gel silicone breast implants drove the firm's stock up 32.6% to $55.01 for the quarter, but investor tunnel-vision could keep future stock movement tied to FDA's final decision
You may also be interested in...
Earnings In Brief
CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...
Earnings In Brief
CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...
Groups Differ On Impact Of Silicone Breast Implants On Subgroup Populations
Several women's health advocates are concerned about a dearth of data on the effect of silicone breast implants on different patient subgroups, including African American women and breast cancer survivors, though some plastic surgeons suggest that these worries are overblown